Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2003
10/01/2003CN1446090A Pharmaceutical composition comprising metformin and 5-phenoxyalkyl-2, 4-thiazolidinedione-type derivative
10/01/2003CN1446088A Highly purified simvastatin compositions
10/01/2003CN1446084A Treatment of insulin resistance syndrome
10/01/2003CN1445222A Benzofuran category compound, its preparing method and usage
10/01/2003CN1445220A Lactone category compound of sweetsop as well as new usage in medicines and its preparing method
10/01/2003CN1444978A Medicine combination for reducing blood fat and preventing senescence and its medicines
10/01/2003CN1444939A Usage of total alkaloid of coftis root, phellodendron bark and ÔÇÿSankezhenÔÇÖ as their preparing method
10/01/2003CN1444932A Application of all transconfiguration retinoic acid in preparing weight reduction medicine
10/01/2003CN1122667C Process for preparing N6-substituted deaza adenosine derivatives
10/01/2003CN1122529C Biological diatetic health-care food containing metallic sulfure protein for diabetes and complication and preparation method
10/01/2003CN1122524C Chinese medicine for treating diabetes and its preparing process
10/01/2003CN1122513C Use of compound in medicine for preparation of inhibiting pathological conditions
10/01/2003CN1122511C Nutrient agent and its application
10/01/2003CN1122457C Composition and method for providing nutrition to diabetics
10/01/2003CN1122456C Food and vitamin products containing natural isomer of reduced folates
09/2003
09/30/2003US6627754 Pyrrolo[2,3-d]pyrimidine compounds
09/30/2003US6627653 Anticonvulsant derivatives useful for the treatment of depression
09/30/2003US6627652 Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
09/30/2003US6627637 I kappa B kinase inhibitors for treating various disorders including arthritis
09/30/2003US6627636 Benzo(3,4)pyrido(3,2-a)cycloctenes and benzo(3,4)pyrido-(3,2-a)oxocins, -thiocins or azocines; anticholesterol, antilipemic agents; lowering LDL cholesterol; increasing HDl cholesterol; hypertriglyceridemia and atherosclerosis
09/30/2003US6627633 The compounds also are potent inhibitors of human cellular proliferation. As such, the compounds constitute pharmaceutical compositions with a pharmaceutically acceptable carrier. Such compounds are useful in inhibiting cellular
09/30/2003US6627628 Cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) are able to modulate the body's own production of cyclic guanosine monophosphate (cGMP) and are suitable for
09/30/2003US6627626 Antiinflammation agents and antiarthritic agents colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
09/30/2003US6627625 Beta-lactam antibiotics and beta -lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter by anxiolytic and antiaggressive behavior modification ans enhanced cognition
09/30/2003US6627604 Memno peptides, process for their preparation and use thereof
09/30/2003US6627415 Isolated nucleic acid comprising a nucleotide sequence encoding fibrinogen-like domain; use in diagnosis and treatment of tumor angiogenesis, wound healing, thromboembolic diseases, atherosclerosis and inflammationinflammation
09/30/2003US6627221 Unit dose containing less than 5% by weight of stearic acid lubricant in the outer phase, relative to the total weight have good dissolution rate, heat resistance and storage stability for drugs such as ibandronate sodium
09/30/2003US6627213 Administering on the same day the infant is fed human breast milk a supplement free of carbohydrate and comprising casein, salts of casein, whey, and casein hydrolysates; decrease of jaundice and increase of excretion of bilirubin
09/30/2003US6627212 Containing titanium dioxide platelets
09/30/2003US6627195 Binding agents to CD23
09/30/2003US6626932 Therapeutic light source and method
09/25/2003WO2003078632A1 Novel receptor polypeptides and polynucleotides encoding the same
09/25/2003WO2003078630A1 INHIBITION OF THE β3 SUBUNIT OF L-TYPE CA2+ CHANNELS
09/25/2003WO2003078623A1 Functional molecule and process for producing the same
09/25/2003WO2003078605A1 A selenium yeast product, a method of preparing a selenium yeast product and the use of the product for preparing food, a dietary supplement or a drug
09/25/2003WO2003078435A1 Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
09/25/2003WO2003078427A1 Azolylaminoazines as inhibitors of protein kinases
09/25/2003WO2003078426A1 Azolylaminoazine as inhibitors of protein kinases
09/25/2003WO2003078425A1 Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt
09/25/2003WO2003078422A1 Novel pyridone derivative
09/25/2003WO2003078413A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity
09/25/2003WO2003078404A1 Pyrimidine derivatives
09/25/2003WO2003078403A2 Derives d’aminoindazoles comme inhibiteurs de proteine-kinase
09/25/2003WO2003078395A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003078379A1 AMORPHOUS Hmg-CoA REDUCTASE INHIBITORS OF DESIRED PARTICLE SIZE
09/25/2003WO2003078376A1 Nk1 antagonists
09/25/2003WO2003078361A1 Controlling chemical reactions by spectral chemistry and spectral conditioning
09/25/2003WO2003077949A2 Methods of treating diabetes using pde 11a inhibitors
09/25/2003WO2003077946A1 Medicinal agent and method for curing pathologic syndrome associated to hemodyscrasia
09/25/2003WO2003077939A1 Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists
09/25/2003WO2003077921A1 Azinylaminoazoles as inhibitors of protein kinases
09/25/2003WO2003077919A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
09/25/2003WO2003077915A1 Use of rapamycin for inhibiting of cell death
09/25/2003WO2003077914A1 N3 alkylated benzimidazole derivatives as mek inhibitors
09/25/2003WO2003077912A1 Method of treatment and/or prophylaxis
09/25/2003WO2003077904A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
09/25/2003WO2003077901A1 Preventing and/or treating cardiovascular disease and/or associated heart failure
09/25/2003WO2003077895A1 Compositions for diabetes
09/25/2003WO2003077882A2 Preparation of sterile stabilized nanodispersions
09/25/2003WO2003077847A2 Substituted amides
09/25/2003WO2003077840A2 Method of modulating inflammatory response
09/25/2003WO2003077832A2 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003WO2003077657A1 Choline-silicic acid complex with osmolytes and divalent trace elements
09/25/2003WO2003070738A3 Topiramate salts and compositions comprising and methods of making and using the same
09/25/2003WO2003041727A3 Plant derived or derivable material with appetite suppressing activity
09/25/2003WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
09/25/2003WO2003039451A3 Thiazole pyridazinones as adenosine antagonists
09/25/2003WO2003029199A9 Benzene derivatives, process for preparing the same and use thereof
09/25/2003WO2003015690A3 Method for treating primary insomnia
09/25/2003WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
09/25/2003WO2003011855A3 Pyrazole-derived kinase inhibitors and uses thereof
09/25/2003WO2002100412A3 Stabilized dispersion of phytosterol in oil
09/25/2003WO2002096357A3 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
09/25/2003WO2002080911A3 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
09/25/2003WO2002064634A3 Human monoclonal antibodies to fc alpha receptor (cd89)
09/25/2003WO2002063004A3 G-protein coupled receptors
09/25/2003WO2002036573B1 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
09/25/2003WO2002032842A3 Compounds with high monoamine transporter affinity
09/25/2003WO2002030884A3 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
09/25/2003WO2002030882A3 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
09/25/2003WO2002014368A3 Proteins and nucleic acids encoding the same
09/25/2003WO2002010378A3 Antisense modulation of ptp1b expression
09/25/2003WO2002004433A3 Melanin concentrating hormone receptor ligands
09/25/2003US20030181764 Acylsulfonamide derivatives containing fluorosubstitutedphenylethynyl group having a hypoglycemic effect and free of the side effect
09/25/2003US20030181728 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
09/25/2003US20030181662 Human procalcitonin and the preparation and use thereof
09/25/2003US20030181587 Thermoplastic resin composition
09/25/2003US20030181519 Substituted phenyl naphthalenes as estrogenic agents
09/25/2003US20030181517 Treatments using venlafaxine
09/25/2003US20030181512 For therapy and prophylaxis of obesity and hyperlipidemia; side effect reduction
09/25/2003US20030181508 For therapy of attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder
09/25/2003US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
09/25/2003US20030181498 For therapy of disease mediated by interation of Vascular Cell Adhesion Molecule-1 (VCAM-1) and/or fibronectin and integrin receptor and/or alpha 4 beta 1
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181494 For lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels; useful for therapy of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer
09/25/2003US20030181491 C2-disubstituted indan-1-ol compounds, their derivatives, processes for their preparation, and their use as pharmaceuticals
09/25/2003US20030181481 Therapeutic drugs for treating central nervous system disorders
09/25/2003US20030181477 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/25/2003US20030181476 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
09/25/2003US20030181461 Use of phosphodiesterase antagonists to treat insulin resistance
1 ... 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 ... 1298